Parkinson disease patient’s awareness of hyperkinetic movements
Objective: The aim of this study was to quantitively compare how PD patients perceive tremor and dyskinesia. Background: Hyperkinetic movements, such as dyskinesia and tremor,…Detection of Levodopa induced Dyskinesia based on spectral features from subthalamic-LFP and sensorimotor-ECoG
Objective: To detect the presence of Levodopa induced Dyskinesia (LID) in Parkinson’s disease (PD) patients based on spectral characteristics from invasive cortico-subthalamic recordings using machine…Impact of istradefylline on the onset of dyskinesia in Parkinson’s Disease patients with wearing off: a randomized controlled study (ODYSSEI)
Objective: To determine the effect of long-term treatment with istradefylline (IST) on the time to onset of dyskinesia in Parkinson’s disease (PD) patients with wearing-off…Basal ganglia shape in de novo Parkinson’s disease patients can predict the onset of Levodopa Induced Dyskinesias
Objective: In the current study, we aimed to examine structural MRI data from a large sample of de novo PD patients and to identify potential…Effect of ADX-88178, a highly-selective mGlu4 PAM, on parkinsonism, dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Objective: To investigate the effect of the metabotropic glutamate 4 (mGlu4) positive allosteric modulator (PAM) ADX-88178 on parkinsonism, dyskinesia and psychosis-like behaviours (PLBs) in the…COPS: Continuous Observation of Parkinsonian Symptoms – A prospective data acquisition study using wearable accelerometery
Objective: To investigate the continuous and objective assessment of motor symptom severity in Parkinson’s Disease (PD) in everyday life. Background: Treatment adjustments in PD patients…Safety and pharmacokinetics of anti-inflammatory NE3107 treatment in carbidopa/levodopa-treated patients with Parkinson’s disease: A phase 2a, double-blind, placebo-controlled study
Objective: To assess the safety, tolerability, and pharmacokinetics (PK) of NE3107 in carbidopa/levodopa (C/L)-treated patients with Parkinson’s disease (PD) Background: Disease-modifying therapies that augment the…Effect of the 5-HT2A/2C inverse agonist nelotanserin on dyskinesia in the MPTP-lesioned marmoset
Objective: To determine the effect of the serotonin 2A/2C (5-HT2A/2C) receptor inverse agonist nelotanserin on dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset. Background: Nelotanserin is a…Dopamine Receptor Gene Polymorphism in L-Dopa Induced Dyskinesia- A Study from Eastern India
Objective: We intended to find the frequency of Single Nucleotide Polymorphism (SNP) rs6280 in DRD3 gene in PD patients with and without Levodopa Induced Dyskinesia…Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 40
- Next Page »